Washington Insider: Open Payments

Share this article:
Tom Sullivan
Tom Sullivan

In August 2013 the Centers for Medicare and Medicaid Services (CMS) launched the Open Payments system. Applicable manufacturers (Pharma, Device and Bio) must use this website to comply with the Physician Payments Sunshine Act.

Open Payments has experienced quite a few glitches. Manufacturers faced delays from CMS for submitting data; physicians and teaching hospitals had a five-month delay to even be allowed to register to review their payments. Manufacturers had to submit detailed datasets and attest to their accuracy inside a three-week window. The time crunch worsened an already complicated, time-consuming registration process.

The problems continue. Manufacturers had difficulties uploading data. In early August, CMS had to take the review website for physicians and teaching hospitals down due to errors in the data from a mix-up in the software (it returned Aug. 15). One would think CMS would keep its head down during such times, but in July, they proposed another set of changes to Open Payments.

These problems and changes have set ablaze criticism over the Sunshine Act's implementation and regulations.  In August, more than 100 physician organizations including the American Medical Association requested that CMS delay the release of the data by six months. They also want to ensure that the exemption for accredited CME remains in place.

One day the physician payment data will be published. It is important to let patients know that these payments represent collaborations between manufactures and physicians that are vital to creating better therapies that will benefit them and their children.


Tom Sullivan is president, Rockpointe Corporation, an accredited CME company.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?